CA2170158A1 - Inhibiteurs de la secretion de tnf-alpha - Google Patents

Inhibiteurs de la secretion de tnf-alpha

Info

Publication number
CA2170158A1
CA2170158A1 CA002170158A CA2170158A CA2170158A1 CA 2170158 A1 CA2170158 A1 CA 2170158A1 CA 002170158 A CA002170158 A CA 002170158A CA 2170158 A CA2170158 A CA 2170158A CA 2170158 A1 CA2170158 A1 CA 2170158A1
Authority
CA
Canada
Prior art keywords
compound
alkyl
tnf
compound according
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002170158A
Other languages
English (en)
Inventor
Roy A. Black
Jeffrey N. Fitzner
Paul R. Sleath
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2170158A1 publication Critical patent/CA2170158A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

L'invention concerne des composés et des procédés efficaces pour inhiber l'enzyme de conversion de TNF- alpha (facteur de nécrose tumorale) (TACE) responsable du clivage du précurseur du TNF- alpha , de façon à obtenir un TNF- alpha biologiquement actif. Les composés utilisés dans l'invention sont des dérivés de peptidyle possédant des groupes actifs capables d'inhiber TACE, tels que des hydroxamates, des thiols, des phosphoryles et des carboxyles.
CA002170158A 1993-08-23 1994-08-19 Inhibiteurs de la secretion de tnf-alpha Abandoned CA2170158A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11060193A 1993-08-23 1993-08-23
US08/110,601 1993-08-23
US18301994A 1994-01-18 1994-01-18
US08/183,019 1994-01-18
PCT/US1994/009343 WO1995006031A1 (fr) 1993-08-23 1994-08-19 Inhibiteurs de la secretion de facteur alpha de necrose tumorale

Publications (1)

Publication Number Publication Date
CA2170158A1 true CA2170158A1 (fr) 1995-03-02

Family

ID=26808203

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002170158A Abandoned CA2170158A1 (fr) 1993-08-23 1994-08-19 Inhibiteurs de la secretion de tnf-alpha

Country Status (8)

Country Link
EP (1) EP0715619A4 (fr)
JP (1) JPH09503201A (fr)
AU (2) AU687436B2 (fr)
CA (1) CA2170158A1 (fr)
FI (1) FI960803A (fr)
NO (1) NO960723L (fr)
NZ (1) NZ271893A (fr)
WO (1) WO1995006031A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT77282A (hu) 1994-10-05 1998-03-30 Darwin Discovery Limited Peptidvegyületek és gyógyászati alkalmazásuk metalloproteáz inhibitorokként
CA2217859A1 (fr) * 1995-05-10 1996-11-14 David Alan Owen Composes de peptidyle inhibant la liberation de metalloproteinases et de tnf, et leurs utilisations therapeutiques
AU706064B2 (en) * 1995-05-10 1999-06-10 Darwin Discovery Limited Peptide compounds which inhibit metalloproteinase and TNF liberation, and their therapeutic use
EP0826000B1 (fr) * 1995-05-10 2002-10-23 Darwin Discovery Limited Composes peptidiques inhibant la liberation de la metalloproteinase et du tnf et leur utilisation therapeutique
US6406901B1 (en) 1995-06-08 2002-06-18 Immunex Corporation TNF-a converting enzyme
US5883241A (en) * 1995-09-05 1999-03-16 Celltech Therapeutics Limited DNA sequences coding for a human metalloproteinase and variants thereof
IL123430A (en) * 1995-10-05 2001-04-30 Darwin Discovery Ltd Theo-converted peptides as inhibitors for metallic proteinases and TNF release
US5665777A (en) * 1995-11-14 1997-09-09 Abbott Laboratories Biphenyl hydroxamate inhibitors of matrix metalloproteinases
ATE205184T1 (de) 1995-11-23 2001-09-15 British Biotech Pharm Metalloproteinase inhibitoren
GB9607120D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
US5990293A (en) * 1996-09-05 1999-11-23 Celltech Therapeutics Limited Human metalloproteinase, variants thereof and DNA sequence coding therefor
US6462023B1 (en) 1996-09-10 2002-10-08 British Biotech Pharmaceuticals, Ltd. Cytostatic agents
EP0925278B1 (fr) 1996-09-10 2002-07-17 British Biotech Pharmaceuticals Limited Derives cytostatiques d'acide hydroxamique
US5952320A (en) * 1997-01-07 1999-09-14 Abbott Laboratories Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
ZA9818B (en) * 1997-01-07 1998-07-02 Abbott Lab C-terminal ketone inhibitors of matrix metalloproteinases and tnf alpha secretion
US5985911A (en) * 1997-01-07 1999-11-16 Abbott Laboratories C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion
WO1998057657A1 (fr) * 1997-06-18 1998-12-23 The Rockefeller University Procedes d'identification d'anticorps et de peptides utiles dans le traitement du choc septique et de l'arthrite experimentale; utilisation de ces derniers
CA2316296A1 (fr) * 1997-10-10 1999-04-22 Imperial College Of Science, Technology And Medicine Emploi de composes de csaidtm pour le traitement des contractions uterines
GB9810464D0 (en) * 1998-05-16 1998-07-15 British Biotech Pharm Hydroxamic acid derivatives
US6329400B1 (en) 1998-08-26 2001-12-11 Glaxo Wellcome Inc. Formamide compounds as therapeutic agents
GB9818605D0 (en) 1998-08-26 1998-10-21 Glaxo Group Ltd Formamide compounds as therepeutic agents
US6172064B1 (en) 1998-08-26 2001-01-09 Glaxo Wellcome Inc. Formamides as therapeutic agents
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
WO2000018358A2 (fr) * 1998-09-30 2000-04-06 The Procter & Gamble Company Methode de traitement de la chute des cheveux au moyen de cetoamides
WO2000018361A2 (fr) * 1998-09-30 2000-04-06 The Procter & Gamble Company Procede de traitement de la chute de cheveux par administration de sulfonamides
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
US6329550B1 (en) 1998-12-31 2001-12-11 Aventis Pharmaceuticals Inc. Amidomalonamides useful as inhibitors of MMP of matrix metalloproteinase
AU2436600A (en) * 1999-01-13 2000-08-01 Jomaa Pharmaka Gmbh Use of 3-isoxazolidinones and hydroxylamine acids for the treatment of infections
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
GB9922825D0 (en) * 1999-09-25 1999-11-24 Smithkline Beecham Biolog Medical use
WO2002006227A1 (fr) * 2000-07-18 2002-01-24 Chugai Seiyaku Kabushiki Kaisha Inhibiteurs de la metalloprotease matricielle
WO2002028829A2 (fr) * 2000-09-25 2002-04-11 Questcor Pharmaceuticals, Inc. Inhibiteurs de peptide deformylase
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
CN113194954A (zh) 2018-10-04 2021-07-30 国家医疗保健研究所 用于治疗角皮病的egfr抑制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0207097B1 (fr) * 1984-12-19 1990-08-08 Ciba-Geigy Ag Nouveaux esters d'acide carbonique
FR2609289B1 (fr) * 1987-01-06 1991-03-29 Bellon Labor Sa Roger Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes
GB9102635D0 (en) * 1991-02-07 1991-03-27 British Bio Technology Compounds
AU2228292A (en) * 1991-06-14 1993-01-12 Research Corporation Technologies, Inc. Peptide derivatives of collagenase inhibitor
GB9215665D0 (en) * 1992-07-23 1992-09-09 British Bio Technology Compounds
GB9323165D0 (en) * 1993-11-10 1994-01-05 Chiros Ltd Compounds
GB9411088D0 (en) * 1994-06-03 1994-07-27 Hoffmann La Roche Hydroxylamine derivatives

Also Published As

Publication number Publication date
JPH09503201A (ja) 1997-03-31
FI960803A0 (fi) 1996-02-22
EP0715619A1 (fr) 1996-06-12
WO1995006031A1 (fr) 1995-03-02
AU5030298A (en) 1998-03-05
AU7569494A (en) 1995-03-21
NO960723D0 (no) 1996-02-23
EP0715619A4 (fr) 1997-03-19
FI960803A (fi) 1996-04-22
NO960723L (no) 1996-02-23
NZ271893A (en) 1997-11-24
AU687436B2 (en) 1998-02-26

Similar Documents

Publication Publication Date Title
US5594106A (en) Inhibitors of TNF-α secretion
CA2170158A1 (fr) Inhibiteurs de la secretion de tnf-alpha
JP3205558B2 (ja) 新規ペプチド誘導体
KR890003603B1 (ko) 5-아미노-2,5-이치환된-4-하이드록시펜타노산 잔기를 함유하는 레닌 억제물의 제조방법
KR20160081897A (ko) 면역조절제로서 1,2,4-옥사디아졸 유도체
KR20160081898A (ko) 면역조절제로서 1,3,4-옥사디아졸 및 1,3,4-티아디아졸 유도체
EP0618223A2 (fr) Peptides inhibent la libération d'interleukine 1-bêta utiles comme agents antiinflammatoires
JP2002517508A (ja) Ｃ型肝炎ウィルスｎｓ３プロテアーゼのペプチド系抑制剤
JPH11514330A (ja) ペプチドおよびペプチドアナログプロテアーゼ阻害剤
US6235717B1 (en) Pharmaceutical compounds
US6995177B1 (en) HCV NS3 protease inhibitors
JPH11292840A (ja) ノルスタチン誘導体又はその塩
JP4116097B2 (ja) 成長ホルモン放出特性をもつ化合物
EP0659193B1 (fr) Inhibiteurs de l'agregation plaquettaire
IL102646A (en) Non-peptidic surrogates of the ldv sequence and pharmaceutical compositions comprising them
AU722421B2 (en) Compounds with growth hormone releasing properties
JPS60136595A (ja) 置換エチレンジアミン誘導体、その製造方法及び該誘導体を含む医薬製剤
US5218089A (en) Retro-inverso analogues of thymopentin and the method for their synthesis
AU703854B2 (en) Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides
US5089476A (en) Glutamic acid derivatives
AU600549B2 (en) Novel compounds
US6180759B1 (en) Process for the preparation of azacycloalkylakanoyl pseudotetrapeptides
EP0393786B1 (fr) Rétro-inverso peptides, analogues de la thymopentine ayant une ou plusieurs liaisons, procédés pour les préparer et leur utilisation pour confectionner un médicament
EP0406931B1 (fr) Analogues de la thymopentine avec toutes les liaisons rétro-inverties, leur méthode de préparation et leur utilisation pour la préparation de compositions pharmaceutiques
EP0375058B1 (fr) Analogues de la thrymopentine, leur procédé de préparation et leur emploi pour préparer des compositions pharmaceutiques

Legal Events

Date Code Title Description
FZDE Dead